BLRX Key Statistics, Chart & Performance
The current stock price of BLRX is 3.1 USD. In the past month the price increased by 3%. In the past year, price decreased by -29.32%.
BLRX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BLRX. When comparing the yearly performance of all stocks, BLRX is a bad performer in the overall market: 86.48% of all stocks are doing better.
BLRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BLRX. BLRX has a bad profitability rating. Also its financial health evaluation is rather negative.
BLRX Financial Highlights
Over the last trailing twelve months BLRX reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS increased by 87.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.48% | ||
| ROE | -15.24% | ||
| Debt/Equity | 0.34 |
BLRX Forecast & Estimates
BLRX Ownership
About BLRX
Company Profile
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Company Info
BIOLINERX LTD-SPONS ADR
Modi'in Technology Park, 2 HaMa'ayan Street
Modiin 7177871 IL
CEO: Philip A. Serlin
Employees: 28
Phone: 97286429100
BIOLINERX LTD-SPONS ADR / BLRX FAQ
Can you describe the business of BIOLINERX LTD-SPONS ADR?
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Can you provide the latest stock price for BIOLINERX LTD-SPONS ADR?
The current stock price of BLRX is 3.1 USD. The price increased by 4.62% in the last trading session.
Does BLRX stock pay dividends?
BLRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of BLRX stock?
BLRX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Would investing in BIOLINERX LTD-SPONS ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BLRX.
Can you provide the ownership details for BLRX stock?
You can find the ownership structure of BIOLINERX LTD-SPONS ADR (BLRX) on the Ownership tab.
What is the outstanding short interest for BIOLINERX LTD-SPONS ADR?
The outstanding short interest for BIOLINERX LTD-SPONS ADR (BLRX) is 5.21% of its float.